

Luca Navarini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1694776/publications.pdf>

Version: 2024-02-01

80
papers

1,537
citations

448610

19
h-index

406436

35
g-index

80
all docs

80
docs citations

80
times ranked

2624
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2022, 41, 641-647.	1.0	6
2	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	0.9	16
3	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. <i>Frontiers in Medicine</i> , 2022, 9, 878797.	1.2	9
4	Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease. <i>Rheumatology</i> , 2022, 62, 321-329.	0.9	15
5	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
6	Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. <i>Scientific Reports</i> , 2022, 12, 7498.	1.6	7
7	Adult-onset Still's disease with elderly onset, results from a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	5
8	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF- β 2 and IL-6. <i>Pharmaceutics</i> , 2022, 15, 622.	1.7	7
9	2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus. <i>Biomedicines</i> , 2022, 10, 1675.	1.4	0
10	Beauty is not perfection: what Leonardo's Lady with an Ermine can suggest to aesthetic surgery. <i>European Journal of Plastic Surgery</i> , 2021, 44, 161-162.	0.3	2
11	JAK inhibitors in immune-mediated rheumatic diseases: From a molecular perspective to clinical studies. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 104, 107789.	1.3	2
12	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	2.5	38
13	Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. <i>Autoimmunity Reviews</i> , 2021, 20, 102750.	2.5	36
14	Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis. <i>Clinical Rheumatology</i> , 2021, 40, 4253-4258.	1.0	12
15	Association Between Minor Salivary Gland Biopsy During Sjögren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 686457.	2.2	6
16	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , 2021, 11, 12455.	1.6	10
17	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 213.	1.6	25
18	Serum resistin is predictive marker of development of new digital ulcers in systemic sclerosis. <i>Clinical and Experimental Medicine</i> , 2021, , 1.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Erythema Multiforme Induced by Secukinumab. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e177-e178.	0.5	4
20	Long-term safety of rituximab in primary Sjögren's syndrome: the experience of a single centre. <i>Journal of Rheumatology</i> , 2021, , jrheum.210441.	1.0	1
21	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 995-1002.	0.4	2
22	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
23	Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. <i>Rheumatology International</i> , 2020, 40, 951-958.	1.5	34
24	New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 75-76.	0.6	9
25	Enteropathic spondyloarthritis: Results from a large nationwide database analysis. <i>Autoimmunity Reviews</i> , 2020, 19, 102457.	2.5	18
26	Moderate to severe plaque psoriasis, described by PASI $\geq 10\%$, can be associated with higher cardiovascular risk according to seven risk algorithms: Results of a 10-year single-center retrospective study and clinical management of psoriatic patients with cardiovascular risk. <i>Dermatologic Therapy</i> , 2020, 33, e14451.	0.8	4
27	Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment. <i>Rheumatology and Therapy</i> , 2020, 7, 867-882.	1.1	21
28	One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 813-821.	1.4	40
29	Homocysteinylated alpha 1 antitrypsin as an antigenic target of autoantibodies in seronegative rheumatoid arthritis patients. <i>Journal of Autoimmunity</i> , 2020, 113, 102470.	3.0	17
30	Retention rates and identification of factors associated with anti-TNF \pm , anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. <i>Clinical Rheumatology</i> , 2020, 39, 2663-2670.	1.0	17
31	Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 409-420.	1.3	21
32	Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?. <i>Autoimmunity Reviews</i> , 2020, 19, 102524.	2.5	231
33	Metabolic syndrome is associated with better quality of sleep in the oldest old: results from the $\hat{\alpha}$ Mugello Study. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 46.	1.2	1
34	Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 785-796.	0.9	8
35	A longitudinal study on caring behaviors of Italian nursing students. <i>Nurse Education Today</i> , 2020, 88, 104377.	1.4	8
36	A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 1767-1769.	0.9	16

#	ARTICLE	IF	CITATIONS
37	Phase angle could be a marker of microvascular damage in systemic sclerosis. <i>Nutrition</i> , 2020, 73, 110730.	1.1	11
38	Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. <i>Anticancer Research</i> , 2020, 40, 983-990.	0.5	17
39	Secukinumab-induced subacute cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , 2020, 33, e13417.	0.8	10
40	Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future. <i>Journal of Experimental Pharmacology</i> , 2020, 12, 487-502.	1.5	1
41	Demographic and clinical differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis: results from a multicentre retrospective study in the Lazio region of Italy. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 88-93.	0.4	5
42	Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management. <i>Drugs and Aging</i> , 2019, 36, 909-925.	1.3	15
43	The association between duration of remission, fatigue, depression and health-related quality of life in Italian patients with systemic lupus erythematosus. <i>Lupus</i> , 2019, 28, 1705-1711.	0.8	20
44	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	1.6	40
45	Pattern of sleep dysfunction in systemic lupus erythematosus: a cluster analysis. <i>Clinical Rheumatology</i> , 2019, 38, 1561-1570.	1.0	7
46	Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 971-976.	1.0	10
47	Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "without skin psoriasis". <i>Clinical Rheumatology</i> , 2019, 38, 2547-2552.	1.0	21
48	Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-7.	0.5	5
49	The Association of Olfactory Dysfunction, Frailty, and Mortality Is Mediated by Inflammation: Results from the InCHIANTI Study. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	0.9	42
50	Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Journal of Autoimmunity</i> , 2019, 107, 102453.	1.7	17
51	Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 71-76.	1.0	7
52	Pathogenesis of Psoriatic Arthritis. <i>Critical Reviews in Immunology</i> , 2019, 39, 361-377.	1.0	15
53	Clinical features of patients with systemic lupus erythematosus according to health-related quality of life, entity of pain, fatigue and depression: a cluster analysis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 535-539.	0.4	7
54	Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 99, 161-168.	1.2	19

#	ARTICLE	IF	CITATIONS
55	Serum level of endostatin and digital ulcers in systemic sclerosis patients. <i>International Wound Journal</i> , 2018, 15, 424-428.	1.3	4
56	Erectile dysfunction: Imbalance between pro-angiogenic and anti-angiogenic factors in systemic sclerosis. <i>European Journal of Internal Medicine</i> , 2018, 53, e17-e18.	1.0	3
57	Leptin in autoimmune mechanisms of systemic rheumatic diseases. <i>Cancer Letters</i> , 2018, 423, 139-146.	3.2	16
58	In systemic sclerosis, microvascular and hands digital arteries damage correlates with serum levels of endostatin. <i>Microcirculation</i> , 2018, 25, e12449.	1.0	5
59	Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results. <i>Journal of Immunology Research</i> , 2018, 2018, 1-6.	0.9	27
60	Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. <i>PLoS ONE</i> , 2018, 13, e0205506.	1.1	28
61	Physical activity and sedentary behavior in patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2018, 13, e0193728.	1.1	48
62	Parasympathetic activity increases with digital microvascular damage and vascular endothelial growth factor in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 24-27.	0.4	3
63	Inflammation as a mediator of the association between osteoporosis and hearing loss in older subjects: a population-based study. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 1451-1456.	0.5	3
64	Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy. <i>Microvascular Research</i> , 2017, 114, 41-45.	1.1	17
65	Intrarenal arterial stiffness is increased in systemic sclerosis patients with anti-ribonucleic acid polymerase III antibodies. <i>Rheumatology</i> , 2017, 56, 1039-1041.	0.9	2
66	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3	2.5	107
67	Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. <i>Lupus</i> , 2017, 26, 1463-1472.	0.8	35
68	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. <i>Clinical Rheumatology</i> , 2017, 36, 251-260.	1.0	22
69	The relation between, metabolic syndrome and quality of life in patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2017, 12, e0187645.	1.1	16
70	Polyunsaturated fatty acids: any role in rheumatoid arthritis?. <i>Lipids in Health and Disease</i> , 2017, 16, 197.	1.2	56
71	Relationship between leptin and regulatory T cells in systemic lupus erythematosus: preliminary results. <i>European Review for Medical and Pharmacological Sciences</i> , 2016, 20, 636-41.	0.5	24
72	The IL33/ST2 axis in Sjogren syndrome in relation to disease activity. <i>European Review for Medical and Pharmacological Sciences</i> , 2016, 20, 1295-9.	0.5	17

#	ARTICLE	IF	CITATIONS
73	Utility of ultrasound in the diagnosis of chronic worsened gout. Journal of Medical Ultrasonics (2001), 2013, 40, 467-469.	0.6	2
74	Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment. Current Medicinal Chemistry, 2013, 20, 3370-3396.	1.2	71
75	Systemic Lupus Erythematosus Patients with and without Neuropsychiatric Manifestations: A Neck and Transcranial Duplex Sonography Study. International Journal of Immunopathology and Pharmacology, 2012, 25, 1157-1165.	1.0	4
76	Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. Autoimmunity Reviews, 2011, 10, 631-635.	2.5	50
77	Leptin in immuno-rheumatological diseases. Cellular and Molecular Immunology, 2011, 8, 203-212.	4.8	45
78	Matters of the Heart: The Case of TNF-Targeting Drugs. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 79-87.	3.4	3
79	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard. Clinical and Experimental Rheumatology, 0, , .	0.4	0
80	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 0, , .	0.4	0